The role of endomyocardial biopsy (EMB) in the diagnosis and treatment of adult and pediatric cardiovascular disease remains controversial, and the practice varies widely even among cardiovascular centers of excellence. A need for EMB exists because specific myocardial disorders that have unique diagnoses and treatment are seldom diagnosed by noninvasive testing. Informed clinical decision making that weights the risks of EMB against the incremental diagnostic, prognostic, and therapeutic value of the procedure is especially challenging for non-specialists because the relevant published literature is usually cited according to specific cardiac diseases, which are only diagnosed after EMB. To define the current role of EMB in the management of cardiovascular disease, a multidisciplinary group of experts in cardiomyopathies and cardiovascular pathology was convened by the American Heart Association (AHA), the American College of Cardiology (ACC), and the European Society of Cardiology (ESC). The present Writing Group was charged with reviewing the published literature on the role of EMB in cardiovascular diseases, summarizing this information, and making useful recommendations for clinical practice with classifications of recommendations and levels of evidence.

The Writing Group identified 14 clinical scenarios in which the incremental diagnostic, prognostic, and therapeutic value of EMB could be estimated and compared with the procedural risks. The recommendations contained in the present joint Scientific Statement are derived from a comprehensive review of the published literature on specific cardiomyopathies, arrhythmias, and cardiac tumors and are categorized according to presenting clinical syndrome rather than pathologically confirmed disease. The ultimate intent of this document is to provide an understanding of the range of acceptable approaches for the use of EMB while recognizing that individual patient care decisions depend on factors not well reflected in the published literature, such as local availability of specialized facilities, cardiovascular pathology expertise, and operator experience. The use of EMB in the posttransplantation setting is beyond the scope of this document.

This Scientific Statement was approved for publication by the governing bodies of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.
Technique and Risks of EMB

The first nonsurgical techniques for heart biopsy were reported in 1958. In the 1960s the safety of heart biopsy improved, with vascular access through the right external or internal jugular vein, sampling of the right interventricular septum, and designation of the heart borders by right heart catheterization before biopsy. Sakakibara and Konno introduced the use of a flexible bioprome with sharpened cusps that allowed EMB by a pinching as opposed to a cutting technique. Caves et al modified the Konno biopsy forceps (Stanford Caves-Shulz bioprome) to allow percutaneous biopsies through the right internal jugular vein with only local anesthesia and rapid tissue removal. The reusable Stanford-Caves bioprome and its subsequent modifications became the standard device for EMB for approximately 2 decades. Single-use biopromes and sheaths allow access through the right and left jugular or subclavian veins, right and left femoral veins, and right and left femoral arteries and may be associated with lower risk of pyrogen reaction and transmission of infection than reusable biopromes.

The right internal jugular vein is the most common percutaneous access site for right ventricular EMB in the United States. In Germany and Italy, the femoral vein is commonly used for percutaneous access. Sonographic techniques to identify the location, size, and respirophasic variation in size of the internal jugular vein decrease the duration of the procedure and complications. Monitoring should include electrocardiographic rhythm, blood pressure, and pulse oximetry. The subclavian vein also may be used occasionally.

The femoral artery may be used as a percutaneous access site for left ventricular biopsy. This approach requires insertion of a preformed sheath to maintain arterial patency. All arterial sheaths must be maintained under constant pressurized infusion to avoid embolic events. Aspirin or other antiplatelet agents may be used in addition to heparin during left heart biopsy procedures to decrease the risk of systemic embolization. No comparative studies exist on which to base a recommendation for left versus right ventricular biopsy; however, left ventricular biopsy has been used in case series to define cardiomyopathic processes limited to the left ventricle.

EMB usually is performed safely under fluoroscopic guidance. Fluoroscopy is generally better than 2-dimensional echocardiography to guide EMB because it provides more information to the operator about the course of the bioprome and site of biopsy. The echocardiographic technique without fluoroscopy has been used primarily to biopsy intracardiac masses. Some operators use fluoroscopy and echocardiography in combination to enhance entry into the right ventricle and direction of the bioprome. Noninvasive computed tomography (CT) or cardiac magnetic resonance (CMR) imaging may be of value in patients scheduled for EMB. CT scanning may be used to assess the angle of the intraventricular septum relative to the superior vena cava or inferior vena cava. Knowledge of this angle may lessen the risk of inadvertent biopsy of the right ventricular free wall during a fluoroscopically directed biopsy. In addition, CMR detection of a focal disease process may identify the area of the left or right ventricle that would be most likely to demonstrate the underlying pathological process. Three-dimensional echocardiography may enhance visualization and reduce the reliance on radiographic imaging in the future.

The risks of EMB may be divided into those that are acute and those that are delayed. Immediate risks of biopsy include perforation with pericardial tamponade, ventricular or supra-ventricular arrhythmias, heart block, pneumothorax, puncture of central arteries, pulmonary embolization, nerve paresis, venous hematoma, damage to the tricuspid valve, and creation of arterial venous fistula within the heart. The risks of EMB likely vary with the experience of the operator, clinical status of the patient, presence or absence of left bundle-branch block, access site, and possibly bioprome. The use of a long sheath that crosses the tricuspid valve may decrease the risk of bioprome-induced tricuspid valve trauma. Delayed complications include access site bleeding, damage to the tricuspid valve, pericardial tamponade, and deep venous thrombosis. Most complications are known from case reports, and therefore the precise frequency of these events is not known.

The data on EMB risks are derived from several single-center experiences and registries that have been reported in the literature. Fowles and Mason reported an overall complication rate of <1% in >4000 biopsies performed in transplantation and cardiomyopathy patients, including 4 with tamponade (0.14%), 3 pneumothorax, 3 atrial fibrillation, 1 ventricular arrhythmia, and 3 focal neurological complications. Olsen, in an unpublished series referenced by Fowles and Mason, reported an overall complication rate of 1.55% in 3097 cardiomyopathy patients biopsied in Europe. Sekiguchi and Take reported a 1.17% complication rate in a
Table 1. Risks Associated With Endomyocardial Biopsy in 546 Procedures

<table>
<thead>
<tr>
<th>Overall 33 complications (6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheath insertion 15 (2.7%)</td>
</tr>
<tr>
<td>12 (2.0%) arterial puncture during local anesthesia</td>
</tr>
<tr>
<td>2 (0.4%) vasovagal reaction</td>
</tr>
<tr>
<td>1 (0.2%) prolonged venous ooze after sheath removal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biopsy procedure 18 (3.3%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 (1.1%) arrhythmia</td>
</tr>
<tr>
<td>5 (1.0%) conduction abnormalities</td>
</tr>
<tr>
<td>4 (0.7%) possible perforation (pain)</td>
</tr>
<tr>
<td>3 (0.5%) definite perforation (pericardial fluid)</td>
</tr>
<tr>
<td>2 of 3 patients with definite perforation died</td>
</tr>
</tbody>
</table>

The risks of EMB depend on the clinical state of the patient, the experience of the operator, and the availability of expertise in cardiac pathology. If a patient with an indication for EMB presents at a medical center where expertise in EMB and cardiac pathology is unavailable, transfer of the patient to a medical center with such experience should be seriously considered. Additionally, patients with cardiogenic shock or unstable ventricular arrhythmias may require the care of specialists in medical and surgical management of heart failure, including ventricular assist device placement and potentially heart transplantation.

Analysis of EMB Tissue

EMB Processing

Samples should be obtained from >1 region of the right ventricular septum. The number of samples obtained should range from 5 to 10, depending on the studies to be performed, and each sample should be 1 to 2 mm³ in size. The sample must be handled carefully to minimize artifacts and transferred from the bioptome to fixative (10% neutral buffered formalin) by use of a sterile needle and not with forceps. The fixative should be at room temperature to prevent contraction band artifacts. The clinical reason for the biopsy determines how many samples are removed and how they are fixed. In general, at least 4 to 5 samples are submitted for light microscopic examination, but more may be submitted for transmission electron microscopy if the clinical question is anthracycline cardiotoxicity. Transmission electron microscopy may also be helpful for the assessment of suspected infiltrative disorders such as amyloidosis, glycogen storage diseases, lysosomal storage diseases, and occasionally viral myocarditis. For transmission electron microscopy, pieces are fixed in 4% glutaraldehyde at room temperature at the time of EMB. One or more pieces may be frozen for molecular studies, immunofluorescence, or immunohistochemistry that may be required for suspected myocarditis, storage diseases, tumor typing, amyloid classification, or viral genome analysis. Pieces of myocardium can be snap-frozen in OCT-embedding medium and stored at −80 °F for immunohistochemical or liquid nitrogen molecular studies. Flash-freezing is suitable for culture, polymerase chain reaction (PCR), or reverse transcriptase PCR (rtPCR) for the identification of viruses, but flash-freezing is not ideal for standard histological preparation because of ice crystal artifacts and cell culture.

Light Microscopic Examination and Stains

For routine light microscopy examination, EMB tissue is embedded in paraffin, and serial sections are obtained and sequentially numbered. For suspected myocarditis, many laboratories will stain every third piece for hematoxylin and eosin and the middle 2 pieces for Movat or elastic trichrome stain to visualize collagen and elastic tissue. Many laboratories also routinely stain 1 slide for iron on men and all postmenopausal women, regardless of the indication for EMB. Congo red staining may be performed on 10- to 15-μm sections to rule out amyloidosis. The remaining slides are usually preserved for immunohistochemistry.

Molecular Biological Detection of Viral Genomes

Recent advances in quantitative (qPCR) and qualitative (nested PCR) molecular techniques can detect fewer than 10 gene copies of viral pathogens in the myocardium. These highly sensitive techniques provide both challenges and opportunities. The clinical impact on prognosis and treatment...
lately depends on establishing a standardized set of diagnostic methods. PCR analysis for viral genomes can yield false results if the sample is not rapidly and properly transported from the catheterization laboratory to the laboratory bench. To prevent sample degradation and contamination, the use of pathogen-free biopsy devices and storage vials is required. New fixatives such as RNA later (Ambion, Austin, Tex) allow PCR and rtPCR to be performed on samples transported on dry ice at room temperature without loss of sensitivity compared with frozen tissue that is transported on ice.

Over the past 2 decades, the use of nested PCR has substantially increased the information about possible cardiotropic viruses in patients with acquired heart disease. Multiple studies of patients with myocarditis or dilated cardiomyopathy (DCM) reported a wide range of viruses, including enteroviruses, adenoviruses, parvovirus B19, cytomegalovirus, influenza and respiratory syncytial virus, herpes simplex virus, Epstein-Barr virus, human herpesvirus 6, HIV, and hepatitis C. In a comprehensive study by Bowles et al, nested PCR amplified a viral product in 40% of 773 samples primarily from patients <18 years of age with myocarditis (n = 624) or DCM (n = 149). In this study, adenovirus and enterovirus genomes were the most frequent. In adults with DCM or unexplained global or regional left ventricular dysfunction, enterovirus, parvovirus B19, human herpes virus 6, or multiple genomes were frequently detected in EMB of consecutively analyzed patients. 

Specialized virological laboratories also use real-time PCR, a more quantitative approach, to estimate viral loads in the majority of cardiotropic viruses. Virus loads have been reported to be between 50 and 500,000 copies/μg in parvovirus B19–positive patients. Unfortunately, the clinical application of real-time PCR is also hampered by sampling error in focal disease and the frequent late timing of EMB after disease onset. Indeed, no published data exist on real-time PCR sampling error or associations of viral loads with clinical outcomes.

Therefore, a limitation for the interpretation of viral genome data remains uncertain sensitivity. Because the number of pieces needed to attain a clinically acceptable sensitivity for cardiotropic viruses is not known, only a positive PCR result is diagnostic, whereas a negative PCR does not exclude viral disease. Because of uncertainties in the methods and interpretation at centers not experienced in these techniques, the Writing Group consensus is that routine testing for viral genomes in EMB specimens is not recommended at this time outside of centers with extensive experience in viral genome analysis.

When Should EMB Be Performed?
Most publications on the use of EMB are only accessible through multiple literature searches by specific pathological diseases, such as lymphocytic myocarditis or giant cell myocarditis (GCM). The Writing Group recognized that a major obstacle to the clinical use of these data is that decisions to proceed with EMB are made on the basis of clinical presentations, not of pathological diagnoses, which are known only after the procedure. To create a set of clinically useful recommendations, the writing group members extracted and synthesized the presenting scenarios from pathology-focused publications in which EMB was used to obtain tissue. The novel result of this effort is a set of distinct clinical scenarios from which a practical decision to proceed with EMB can be made.

One broad conclusion of the committee members is that EMB is not commonly indicated in the evaluation of heart disease. In this regard, the results presented in this Scientific Statement are in agreement with the recommendations for EMB from the current AHA/ACC guideline on the Diagnosis and Management of Chronic Heart Failure in the Adult, the Heart Failure Society of America Heart Failure Practice Guideline, and the ESC Heart Failure guidelines. However, there are specific clinical circumstances in which EMB results may meaningfully estimate prognosis or guide treatment. The present Scientific Statement also explores the indications for EMB besides unexplained cardiomyopathy.

Because no randomized, controlled treatment data exist on the utility of biopsy, the recommendations of this writing group are based on case–control series and expert opinion, which are summarized in Table 2.

The definitions of key terms relevant to the clinical scenarios that follow are provided to clarify the interpretation of the committee’s recommendations. Unexplained heart failure refers to a clinical setting where appropriate tests to exclude common forms of cardiomyopathy have been performed and fail to reveal the diagnosis. These tests usually include an ECG, chest radiograph, and echocardiography to identify valvular, congenital, or pericardial causes for heart failure and coronary angiography for the evaluation of coronary artery disease. Other tests may include CT or magnetic resonance imaging, depending on the clinical setting. Throughout this document, “ventricular arrhythmia” refers to ventricular fibrillation or sustained and nonsustained ventricular tachycardia usually associated with hemodynamic compromise.

Clinical Scenario 1
EMB should be performed in the setting of unexplained, new-onset heart failure of <2 weeks’ duration associated with a normal-sized or dilated left ventricle in addition to hemodynamic compromise. Class of Recommendation I, Level of Evidence B.

Adult and pediatric patients who present with the sudden onset of severe left ventricular failure within 2 weeks of a distinct viral illness and who have typical lymphocytic myocarditis on EMB have an excellent prognosis. These patients often are in cardiogenic shock and require intravenous inotropic agents or mechanical assistance for circulatory support. The left ventricle is often thick but not dilated, and the ejection fraction (EF) is markedly depressed. Patients of this type who have lymphocytic myocarditis on EMB are uncommon and poorly represented in the randomized trials of acute myocarditis and cardiomyopathy. Therefore, there are few data on immunosuppressive treatment of fulminating myocarditis in the adult population to assess the efficacy or safety of intravenous immunoglobulin or corticosteroids in this disorder. However, if other causes of heart failure (such
as coronary artery disease) are excluded, EMB can provide unique prognostic information and exclude clinically more aggressive disorders.

GCM and necrotizing eosinophilic myocarditis may present with a fulminant clinical course, but unlike fulminant lymphocytic myocarditis, both disorders have a poor prognosis. Necrotizing eosinophilic myocarditis is a rare condition known only from small case series and case reports. The prognosis is poor, with most cases diagnosed at autopsy. This form of eosinophilic heart disease is characterized by an acute onset and rapid progression of hemodynamic compromise. Histologically, necrotizing eosinophilic myocarditis may be identified by a diffuse inflammatory infiltrate with predominant eosinophils associated with extensive myocyte necrosis. Necrotizing eosinophilic myocarditis differs from typical hypersensitivity myocarditis (HSM) in that the lesions are diffuse rather than perivascular and interstitial, and myocyte necrosis is prominent. A histological diagnosis on EMB alters prognosis and would lead to immunosuppressive therapy.

Therapy with combinations of immunosuppressive agents has been associated with improved outcome in GCM and necrotizing eosinophilic myocarditis. The sensitivity of EMB for lymphocytic myocarditis is variable and depends on the duration of illness. In subjects with symptom duration of <4 weeks, up to 89% may have lymphocytic myocarditis, but generally the yield is lower, between 10% and 35% depending on the “gold standard” used. In contrast, the sensitivity of EMB for GCM is 80% to 85% in subjects who subsequently die or undergo heart transplantation. In the setting of anticipated mechanical circulatory device support, a pathological diagnosis of GCM may lead to use of a biventricular device because of the likelihood of progressive right ventricular failure. Thus, EMB may provide unique and clinically meaningful information and should be performed in the setting of unexplained, new-onset heart failure of <2 weeks’ duration associated with a normal-sized or dilated left ventricle in addition to hemodynamic compromise.

Clinical Scenario 2
EMB should be performed in the setting of unexplained new-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, Mobitz type II second- or third-degree atrioventricular (AV) heart block, or failure to respond to usual care within 1 to 2 weeks. Class of Recommendation I, Level of Evidence B.

Although most cases of acute DCM are relatively mild and resolve with few short-term sequelae, certain signs and symptoms predict GCM, a disorder with a mean transplantation-free survival duration of only 5.5 months. GCM is associated with a variety of autoimmune disorders, thymoma, and drug hypersensitivity. At presentation, ventricular tachycardia is present in 15% of cases, complete heart block in 5%, and an acute coronary syndrome in 6%—rates higher than are typically seen in noninflammatory DCM. In follow-up, 29% of GCM patients developed ventricular tachycardia and 15% developed AV block (8% complete). Thus, clinical clues to suggest GCM and prompt an EMB include association with other autoimmune disorders.
or thymoma, failure to respond to usual care, and the presence of complete heart block or ventricular tachycardia.

Patients with acute heart failure due to GCM respond well to heart transplantation. Alternatively, treatment with combination immunosuppression may improve transplantation-free survival duration compared with patients with GCM not receiving immunosuppressive treatment. Patients treated without immunosuppressive therapy had a median transplantation-free survival duration of 3.0 months, compared with a 12.3-month ($P=0.003$) median transplantation-free survival duration for patients treated with cyclosporine-based immunosuppression. Therefore, a diagnosis of GCM will affect prognosis and treatment. A comparison of survival between patients in the multicenter Giant Cell Myocarditis Registry and those from the Myocarditis Treatment Trial (lymphocytic myocarditis) showed that patients with GCM had a significantly poorer prognosis. At 4 years, only 11% of patients with GCM were alive without transplantation, compared with 44% of patients with lymphocytic myocarditis.

On the basis of these reports, the Writing Group recommends that EMB be performed in the setting of unexplained, new-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, Mobitz type II second- or third-degree AV heart block, or failure to respond to usual care within 1 to 2 weeks.

**Clinical Scenario 3**

EMB is reasonable in the clinical setting of unexplained heart failure of $>3$ months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, Mobitz type II second- or third-degree AV heart block, or failure to respond to usual care within 1 to 2 weeks. *Class of Recommendation IIa, Level of Evidence C.*

Patients who present with heart failure of $>3$ months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks are at risk for cardiac sarcoidosis or idiopathic granulomatous myocarditis. Cardiac sarcoidosis is present in $\sim 25\%$ of patients with systemic sarcoidosis, but symptoms referable to cardiac sarcoidosis occur in only $5\%$ of sarcoid patients and up to $50\%$ of patients with granulomatous inflammation in the heart have no evidence of extracardiac disease. Patients with cardiac sarcoidosis sometimes may be distinguished from those with DCM by a high rate of heart block ($8\%$ to $67\%$) and ventricular arrhythmias ($29\%$). The rates of ventricular tachycardia and heart block are therefore similar in cardiac sarcoidosis and GCM, but cardiac sarcoidosis generally has a more chronic course.

Histologically, sarcoidosis consists of noncaseating granulomas with fibrosis, few eosinophils, and little myocyte necrosis. In a study of 26 patients in whom cardiac sarcoidosis was strongly suspected on the basis of clinical diagnostic criteria for sarcoidosis, ECG abnormalities, or noninvasive imaging, noncaseating granulomata were found in only $19.2\%$ of the patients, which confirmed earlier reports that the sensitivity of EMB for sarcoidosis is $\sim 20\%$ to $30\%$. Thus, the heterogeneous myocardial distribution of sarcoid heart disease may lead to sampling error and decrease the diagnostic rate of the EMB. In patients with biopsy-proven pulmonary sarcoid, CMR has been used to infer cardiac involvement and localize disease activity.

Even though the diagnostic rate of the EMB in cardiac sarcoidosis is low, a histological distinction between cardiac sarcoidosis and GCM (both of which have giant cells) is important for therapeutic decisions and prognosis. The rate of transplantation-free survival at 1 year is significantly worse in patients diagnosed by EMB with idiopathic GCM than in patients with cardiac sarcoidosis ($21.9\%$ versus $69.8\%; P<0.0001$). Reports differ as to whether survival rate in cardiac sarcoidosis is similar to or worse than in DCM.

Sarcoidosis may respond to treatment with corticosteroids. Rate of survival was better in those who received corticosteroids than in those who received usual care ($64\%$ versus $40\%; P=0.048$) in one retrospective study. Small case series and case reports also suggest that corticosteroids may improve clinical status and ventricular function, particularly if used early in the course of disease, but their benefit on ventricular arrhythmias is less certain. Implantable cardiac defibrillators may be effective in treating arrhythmias in patients with ventricular tachycardia related to sarcoidosis. After extensive fibrosis of the left ventricle, steroid use is probably of little benefit. Therefore, EMB is reasonable in the clinical setting of unexplained heart failure of $>3$ months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, Mobitz type II second- or third-degree AV heart block, or failure to respond to usual care within 1 to 2 weeks.

**Clinical Scenario 4**

EMB is reasonable in the setting of unexplained heart failure associated with a DCM of any duration that is associated with suspected allergic reaction in addition to eosinophilia. *Class of Recommendation IIa, Level of Evidence C.*

HSM is an uncommon disorder with a wide range of presentations, including sudden death, rapidly progressive heart failure, or more chronic DCM. Clinical clues that are reported in a minority of cases include rash, fever, and peripheral eosinophilia. A temporal relation with recently initiated medications or the use of multiple medications is usually present. The ECG is often abnormal, with nonspecific ST-segment changes or infarct patterns similar to other forms of acute myocarditis. The prevalence of clinically undetected HSM in explanted hearts ranges from $2.4\%$ to $7\%$ and has been associated with dobutamine.

Early suspicion and recognition of HSM may lead to withdrawal of offending medications and administration of high-dose corticosteroids. The hallmark histological findings of HSM include an interstitial infiltrate with prominent eosinophils with little myocyte necrosis; however, GCM, granulomatous myocarditis, or necrotizing eosinophilic myocarditis may also be a manifestation of drug hypersensitivity and may be distinguished from common forms of HSM only by EMB.

Eosinophilic myocarditis associated with the hypereosinophilic syndrome is a form of eosinophilic myocarditis that typically evolves over weeks to months. The presentation is usually biventricular heart failure, although arrhythmias may lead to sudden death. Usually hypereosinophilia precedes or
coincides with the onset of cardiac symptoms, but the eosinophilia may be delayed.79 Eosinophilic myocarditis may also occur in the setting of malignancy or parasite infection and early in the course of endocardial fibrosis. Because EMB may distinguish HSM from GCM or necrotizing eosinophilic myocarditis, EMB is reasonable in the setting of unexplained heart failure associated with a DCM of any duration associated with suspected allergic reaction in addition to eosinophilia.

Clinical Scenario 5
EMB is reasonable in the setting of unexplained heart failure associated with suspected anthracycline cardiomyopathy. Class of Recommendation IIa, Level of Evidence C.

Certain chemotherapeutic agents, particularly anthracyclines, are known to be cardiotoxic, particularly at higher cumulative doses. Although cardiotoxicity may be monitored by several modalities, including echocardiographic or radionuclide angiography assessment of EF, fractional shortening, or parameters of diastolic dysfunction, these modalities are generally regarded as capable of detecting more advanced stages of cardiotoxicity rather than earlier degrees of cardiotoxicity. Nevertheless, these techniques are noninvasive and thus widely used in routine clinical practice. EMB, though an invasive procedure, is considered to be the most sensitive and specific means of evaluating cardiotoxicity.

Examination of biopsy specimens in anthracycline-induced cardiomyopathy with electron microscopy demonstrates characteristic changes, including extensive depletion of myofibrillar bundles, myofibrillar lysis, distortion and disruption of the Z-lines, mitochondrial disruption, and intramyocyte vacuolation.76 A grading system is used to score toxicity on the basis of the percentage of biopsy specimen cells that demonstrate associated toxicity, with a score of 1 indicating <5% biopsy specimen cell involvement and 3 representing >35% involvement.76,77

Early study of the procedure demonstrated that in patients with risk factors, the use of EMB, along with hemodynamic data, reduced the rate of doxorubin-induced heart failure when compared with monitoring without invasive studies.78 A good correlation was found between cumulative Adriamycin dose and EMB grade (although the correlation between changes in biopsy grade and EF was poor).79 In one series, patients with a biopsy grade ≥1.5 had a >20% chance of cardiac failure with continued therapy.80 With its ability to detect earlier stages of cardiac toxicity, as well as its sensitivity and specificity, EMB has been used in studies of newer chemotherapeutic agents and regimens.81–84 The threshold to perform biopsy may also be influenced by the prior use of concomitant therapies known to potentiate anthracycline-induced cardiotoxicity, including radiation, herceptin, and cyclophosphamide.

Given its invasive nature, EMB in patients treated with chemotherapeutic agents may be best suited for situations in which there is question as to the cause of cardiac dysfunction,76 as well as in select cases in which ultimate administration of greater than the usual upper limit of an agent is believed to be desirable, and in clinical studies of chemotherapeutic-related toxicity of newer agents and regimens.85,86

Clinical Scenario 6
EMB is reasonable in the setting of heart failure associated with unexplained restrictive cardiomyopathy. Class of Recommendation IIa, Level of Evidence C.

Of the 3 major functional categories of the cardiomyopathies (dilated, hypertrophic, and restrictive), restrictive cardiomyopathy is the least common form in adults and in children. Typically, a patient presents with symptoms of heart failure and on echocardiogram is found to have normal or decreased volume of both ventricles, biatrial enlargement, normal or minimally increased wall thickness with no valvular abnormality, or normal or near-normal systolic function with impaired diastolic filling, for example, restrictive physiology. As shown in Table 3, this category of cardiomyopathy has been further classified into noninfiltrative processes, infiltrative disorders, and storage diseases that cause characteristic ventricular filling abnormalities, as well as the endomyocardial diseases that have many of the same clinical manifestations.87 Thus, a variety of pathological processes may result in restrictive cardiomyopathy, although the cause often remains unknown. More importantly, the clinical and

<table>
<thead>
<tr>
<th>Myocardial</th>
<th>Endomyocardial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noninfiltrative</td>
<td>Endomyocardial fibrosis*</td>
</tr>
<tr>
<td>Idiopathic cardiomyopathy*</td>
<td>Hypereosinophilic syndrome</td>
</tr>
<tr>
<td>Familial cardiomyopathy</td>
<td>Carcinoid heart disease</td>
</tr>
<tr>
<td>Hypertrophic cardiomyopathy</td>
<td>Metastatic cancers</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>Radiation*</td>
</tr>
<tr>
<td>Pseudoxanthoma elasticum</td>
<td>Toxic effects of anthracycline*</td>
</tr>
<tr>
<td>Diabetic cardiomyopathy</td>
<td>Drugs causing fibrous endocarditis (serotonin, methysergide, ergotamine, mercurial agents, busulfan)</td>
</tr>
</tbody>
</table>

*This condition is more likely than the others to be encountered in clinical practice.

Adapted from Kushwaha et al87 with permission from the Massachusetts Medical Society. Copyright 1997, The Massachusetts Medical Society.
hemodynamic features of many types of restrictive cardiomyopathy may mimic those of constrictive pericarditis. EMB, in combination with either CT or CMR, can be helpful in differentiating the 2 clinical entities restrictive cardiomyopathy and constrictive pericarditis. EMB may reveal either a specific infiltrative disorder, for example, amyloidosis or hemochromatosis, or myocardial fibrosis and myocyte hypertrophy consistent with idiopathic restrictive cardiomyopathy. However, if pericardial thickening is noted on CT or CMR and the physiology is most consistent with constrictive pericarditis, EMB is often not needed. Because of the frequency of treatable disorders, EMB is reasonable in the setting of heart failure associated with unexplained restrictive cardiomyopathy.

**Clinical Scenario 7**

**EMB is reasonable in the setting of suspected cardiac tumors, with the exception of typical myxomas. Class of Recommendation IIa, Level of Evidence C.**

There are several dozen case reports and one small series of EMB being used for the tissue diagnosis of cardiac tumors. Over the past decade, such biopsy usually has been performed with the aid of transesophageal echocardiography. Lesions have been biopsied in all 4 cardiac chambers, though most reports are of right-sided tumors. Biopsy has resulted in diagnoses such as primary cardiac lymphoma, non-Hodgkin’s lymphoma, cardiac sarcoma, cervical carcinoma, melanoma, hepatocellular carcinoma, and pulmonary microcystoma; lymphoma is the most commonly reported tumor. Most tumors were suspected, although several have been serendipitously discovered during biopsy for other indications. The actual yield of EMB for suspected cardiac tumor cannot be defined because the number of nondiagnostic and unpublished procedures could never be determined. Similarly, the complication rate of such procedures cannot be definitively determined, although none of the published reports of EMB for suspected tumor note any major complications. Because right heart myxomas can embolize to the lungs with manipulation, EMB is not usually warranted if the appearance is typical on noninvasive imaging.

Therefore, EMB for suspected cardiac tumor seems a reasonable procedure if (1) the diagnosis cannot be established by noninvasive modalities (such as cardiac CMR) or less invasive (noncardiac) biopsy; (2) tissue diagnosis can be expected to influence the course of therapy; (3) the chances of successful biopsy are believed to be reasonably high; and (4) the procedure is performed by an experienced operator. Guidance with transesophageal echocardiography or CMR is advised when possible.

**Clinical Scenario 8**

**EMB is reasonable in the setting of unexplained cardiomyopathy in children. Class of Recommendation IIa, Level of Evidence C.**

As in adults, the major indications for EMB in children include fulminant or acute unexplained heart failure, cardiac transplant surveillance or rejection evaluation, unexplained arrhythmias, and idiopathic forms of DCM. Rarely, patients with other forms of cardiomyopathy, including arrhythmogenic right ventricular dysplasia cardiomyopathy (ARVD/C), restrictive cardiomyopathy, and hypertrophic cardiomyopathy (HCM), undergo EMB. In nearly all instances, the biopsies are performed in the right ventricle under sedation or anesthesia. The reported experience with EMB in children consists of case reports and case series, and therefore the recommendations of this Writing Group are based on expert opinion.

Most cases of myocarditis in children are viral induced, have acute onset, and present with heart failure, cardiovascular collapse, or unexplained arrhythmias (usually ventricular tachycardia) or conduction disease (typically AV block). The histopathologic picture is similar to that seen in adults, although it appears to be virus specific. For instance, enteroviruses such as coxsackievirus are consistently associated with classic frank myocarditis by histology, whereas adenovirus is most commonly associated with histological features of borderline myocarditis. Parvovirus, Ebstein-Barr virus, and cytomegalovirus appear to have variable histological features.

Outcomes of young children (<1 year of age) with myocarditis appear to be worse than those of older children and also appear to be associated with viral pathogenesis, with adenovirus having the worst prognosis. However, the underlying viruses have changed over the decades, with coxsackievirus common in the 1980s through 1990s, followed by a predominance of adenovirus in the 1990s, and now replaced by parvovirus B19. Similar data have been noted in children after transplantation. Shirali et al demonstrated that children with PCR evidence of adenovirus in EMB samples have a 5-year survival rate of 66%, whereas PCR-negative patients had a 5-year survival rate of 95%. The present Writing Group’s assessment is that EMB is reasonable in the setting of unexplained cardiomyopathy in children (Class of Recommendation IIa, Level of Evidence C).

**Clinical Scenario 9**

**EMB may be considered in the setting of unexplained, new-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks. Class of Recommendation IIb, Level of Evidence B.**

The utility of EMB in patients with DCM of 2 weeks’ to 3 months’ duration is less certain than in patients with <2 weeks of symptoms because most patients with uncomplicated acute idiopathic dilated cardiomyopathy improve with standard heart failure care. Furthermore, several studies have demonstrated a wide variation in the incidence in which the pathological diagnosis of lymphocytic myocarditis is made, ranging from 0% to 63%. This can be attributed to variation in the patient populations studied, sampling error, and variability in pathological interpretation. In cases in which EMB is positive, lymphocytic myocarditis is the most frequent form of myocarditis seen. Studies with a high incidence rate of lymphocytic myocarditis found on biopsy usually involved patients with acute heart failure with symp-
tom onset within 1 month, rather than patients who had had symptoms for months to years. Lack of a consensus definition for diagnosing lymphocytic myocarditis on EMB also contributed to the variation. Formal criteria, called the Dallas criteria, were established in 1986 and were used in the National Heart, Lung, and Blood Institute–sponsored Myocarditis Treatment Trial. The Dallas criteria have been questioned as the gold standard for diagnosis of myocarditis because of sampling error, interobserver variability in histopathologic interpretation, and lack of correlation between Dallas criteria myocarditis and demonstration of viral genomes in heart tissue.

Prognosis varies with results of EMB because the risk of death or heart transplantation in lymphocytic myocarditis with 2 weeks or more of symptoms and lack of a distinct viral prodrome is greater than in fulminant lymphocytic myocarditis described in clinical scenario 1; however, the presence of lymphocytic myocarditis on EMB in this clinical setting rarely affects treatment. For example, in the Myocarditis Treatment Trial, 111 patients with active or borderline myocarditis on EMB and left ventricular EF of <45% were randomized to conventional therapy or a 24-week immunosuppressive regimen consisting of either prednisone and azathioprine or prednisone and cyclosporine. The average symptom duration before treatment was 4 weeks, and the primary end point was the change in EF after 28 weeks. The average EF and the median transplantation-free survival duration were similar in the immunosuppression and conventional therapy groups. The risk of death or transplantation was 56% at 4 years. Similarly, in the Immunoglobulin for Myocarditis and Acute Cardiomyopathy (IMAC-1) trial of intravenous immunoglobulin for acute nonischemic DCM, at 2 years the risk of death or transplantation was 12%. Sixteen percent of patients in the IMAC-1 study had borderline or active myocarditis. Compared the prognosis of patients with acute DCM with and without myocarditis and found that the survival rate in patients with Dallas criteria myocarditis was the same as in those with no inflammation. From these 3 studies, subjects with acute DCM who also have myocarditis as defined by the Dallas criteria do not seem to respond to immunosuppressive therapies, including intravenous immunoglobulin. Therefore, the information gained from the Dallas criteria does not alter prognosis or therapy in most patients. On the basis of these reports, the Writing Group does not recommend performing EMB for the routine evaluation of new-onset heart failure of 2 weeks’ duration associated with a dilated left ventricle, without new ventricular arrhythmias or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks. Class of Recommendation IIb, Level of Evidence C.

Clinical Scenario 10
EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks. Class of Recommendation IIb, Level of Evidence C.

The role of EMB in chronic, symptomatic DCM has been the focus of recent research articles, particularly in viral-associated cardiomyopathy. Some patients who have symptomatic heart failure and DCM after 6 months of optimal therapy may benefit from immunomodulation or antiviral therapy. Two recent trials examined patients with DCM, symptom duration of >6 months, and cardiomyocyte HLA-ABC and HLA-DR antigen expression on EMB. Treatment with atorvastatin or azathioprine and prednisone resulted in improved EF. In both trials, the test used to classify these patients as having persistent immune activation was an immunoperoxidase stain for HLA-ABC or HLA-DR, a more sensitive marker of cardiac inflammation than lymphocyte infiltration. If these data are confirmed in a larger trial with clinically meaningful end points, EMB may have a greater role in the evaluation of chronic DCM.

Another group of patients who may present with chronic DCM are individuals with hereditary or acquired hemochromatosis. Cardiac involvement in hemochromatosis usually can be diagnosed on the basis of history, clinical examination, and echocardiography or CMR demonstrating DCM in the setting of laboratory abnormalities such as elevated serum iron and HFE gene mutation. In the event that findings are equivocal and the possibility of cardiac hemochromatosis still exists, EMB can be useful for diagnosis and to guide treatment. Iron deposition is seen within the sarcoplasm. Treatment with phlebotomy or iron chelation therapy can reverse the ventricular dysfunction.

On the basis of these reports, the Writing Group recognizes that divergent evidence exists with regard to the utility of EMB in this clinical scenario. The Writing Group recommends that EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias, or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks (Class of Recommendation IIb, Level of Evidence C).

Clinical Scenario 11
EMB may be considered in the setting of heart failure associated with unexplained HCM. Class of Recommendation IIb, Level of Evidence C.

HCM occurs in an autosomal dominant pattern in 1:500 of the general population recognized to have the clinical phenotype, which makes it the most frequently occurring cardiomyopathy. HCM may present as sudden cardiac death in the young and may also cause heart failure at any age. HCM is defined by a hypertrophied, nondilated left ventricle in the absence of other systemic or cardiac disease that might result in left ventricular wall thickening to the magnitude that is seen in HCM, eg, systemic hypertension or aortic stenosis.

The diagnosis is made by echocardiography or magnetic resonance imaging, which shows left ventricular wall thickening, small left ventricular cavity, and sometimes a dynamic outflow obstruction. EMB is not usually needed in the evaluation of HCM but may be considered in those cases in which the diagnosis remains equivocal following noninvasive evaluations. EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias, or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks (Class of Recommendation IIb, Level of Evidence C).

Clinical Scenario 12
EMB may be considered in the setting of heart failure associated with unexplained HCM. Class of Recommendation IIb, Level of Evidence C.

HCM occurs in an autosomal dominant pattern in 1:500 of the general population recognized to have the clinical phenotype, which makes it the most frequently occurring cardiomyopathy. HCM may present as sudden cardiac death in the young and may also cause heart failure at any age. HCM is defined by a hypertrophied, nondilated left ventricle in the absence of other systemic or cardiac disease that might result in left ventricular wall thickening to the magnitude that is seen in HCM, eg, systemic hypertension or aortic stenosis.

The diagnosis is made by echocardiography or magnetic resonance imaging, which shows left ventricular wall thickening, small left ventricular cavity, and sometimes a dynamic outflow obstruction. EMB is not usually needed in the evaluation of HCM but may be considered in those cases in which the diagnosis remains equivocal following noninvasive evaluations. EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias, or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks (Class of Recommendation IIb, Level of Evidence C).

Clinical Scenario 13
EMB may be considered in the setting of heart failure associated with unexplained HCM. Class of Recommendation IIb, Level of Evidence C.

HCM occurs in an autosomal dominant pattern in 1:500 of the general population recognized to have the clinical phenotype, which makes it the most frequently occurring cardiomyopathy. HCM may present as sudden cardiac death in the young and may also cause heart failure at any age. HCM is defined by a hypertrophied, nondilated left ventricle in the absence of other systemic or cardiac disease that might result in left ventricular wall thickening to the magnitude that is seen in HCM, eg, systemic hypertension or aortic stenosis.

The diagnosis is made by echocardiography or magnetic resonance imaging, which shows left ventricular wall thickening, small left ventricular cavity, and sometimes a dynamic outflow obstruction. EMB is not usually needed in the evaluation of HCM but may be considered in those cases in which the diagnosis remains equivocal following noninvasive evaluations. EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias, or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks (Class of Recommendation IIb, Level of Evidence C).

Clinical Scenario 14
EMB may be considered in the setting of heart failure associated with unexplained HCM. Class of Recommendation IIb, Level of Evidence C.

HCM occurs in an autosomal dominant pattern in 1:500 of the general population recognized to have the clinical phenotype, which makes it the most frequently occurring cardiomyopathy. HCM may present as sudden cardiac death in the young and may also cause heart failure at any age. HCM is defined by a hypertrophied, nondilated left ventricle in the absence of other systemic or cardiac disease that might result in left ventricular wall thickening to the magnitude that is seen in HCM, eg, systemic hypertension or aortic stenosis.

The diagnosis is made by echocardiography or magnetic resonance imaging, which shows left ventricular wall thickening, small left ventricular cavity, and sometimes a dynamic outflow obstruction. EMB is not usually needed in the evaluation of HCM but may be considered in those cases in which the diagnosis remains equivocal following noninvasive evaluations. EMB may be considered in the setting of unexplained heart failure of >3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias, or Mobitz type II second- or third-degree AV heart block, that responds to usual care within 1 to 2 weeks (Class of Recommendation IIb, Level of Evidence C).
which unexplained wall thickening prompts an effort to exclude infiltrative disorders such as Pompe’s or Fabry’s diseases and noninvasive tests are inconclusive. Occasional patients being considered for surgical myomectomy may benefit from EMB before surgery to exclude Fabry’s disease, which may respond to enzyme replacement therapy.123

Senile, transthyretin-associated, and primary (AL) amyloidosis may have cardiac involvement that results in a dilated, restrictive, or hypertrophic pattern of cardiomyopathy.124 When cardiac amyloidosis is present, low voltage on ECG and left ventricular hypertrophy on echocardiogram strongly support the diagnosis.125 Prognosis in cardiac amyloidosis is much worse if either histological evidence of myocarditis or elevated serum troponin are present.125,126 Immunohistochemistry performed on heart tissue can distinguish among types of amyloidosis, which have specific therapies. Often the diagnosis can be established from less invasive procedures, such as fat pad or bone marrow biopsies; however, in patients in whom clinical evaluation is equivocal, EMB can be used to establish the diagnosis and guide treatment.127

Clinical Scenario 12

EMB may be considered in the setting of suspected ARVD/C. Class of Recommendation IIb, Level of Evidence C.

ARVD/C, an inherited or sporadic form of right and left ventricular cardiomyopathy, is estimated to occur in 1:5000 persons. The disorder involves predominantly the right ventricle, with progressive loss of myocytes that are replaced by fibrofatty tissue, resulting in ventricular dysfunction and tachyarrhythmias, typically monomorphic ventricular tachycardia.128–130 Noninvasive tests, including echocardiography, right ventricular angiography, cardiac CMR, and cardiac CT imaging, often establishes the diagnosis. In a study of the use of CMR in 40 patients with ARVD/C and 20 normal subjects, the sensitivity of fat infiltration, right ventricular enlargement, and regional right ventricular dysfunction for diagnosing ARVD/C was 84%, 68%, and 78%, and specificity was 79%, 96%, and 94%, respectively.131

The use of EMB for ARVD/C has been controversial because of the perceived risk of perforation of the thin-walled right ventricle with fibrofatty replacement, but the few reports of EMB for ARVD/C do not report a high rate of complications.132,133 Within the pediatric population, this disease occurs nearly exclusively in adolescents and young adults, who have a lower risk than infants. Nonetheless, experts in this field disagree as to the risks of the procedure. The histopathologic findings from EMB may be diagnostic of ARVD/C if performed in the appropriate position in the right ventricle.134 Diagnosis relies on the finding of fibrofatty replacement of sufficient degree. Bowles and colleagues135 also demonstrated that some cases are associated with viral genome in the myocardium. A high percentage of biopsy and autopsy studies in patients with ARVD/C have associated inflammatory infiltrates, but the prognostic relevance of these lesions is uncertain. Recognizing that there is a wide spectrum of clinical practice in the use of EMB in the management of suspected ARVD/C and scarce data to inform this practice, the Writing Group recommends that EMB may be considered in the setting of suspected ARVD/C (Class IIb, Level of Evidence C).

Clinical Scenario 13

EMB may be considered in the setting of unexplained ventricular arrhythmias. Class of Recommendation IIb, Level of Evidence C.

There is modest published literature on the use of EMB in patients with primary or idiopathic (eg, without known structural heart disease or predisposing disease) arrhythmias and primary conduction abnormalities. Many of these studies were conducted in the 1980s, and most involve only modest numbers of patients (Table 4).136–142

Most studies reported a high incidence of abnormal findings, although there were usually nonspecific findings; the incidence of histologically diagnosed myocarditis varied widely in these reports, and only rarely were other specific disease entities diagnosed. One authoritative review questioned the “strikingly high” incidence of reported histological myocardial abnormalities in the literature, and the review authors comment that they suspect the true incidence of abnormalities described in these reports to be lower.136 Notably, biopsy is not believed to be able to detect abnormalities that are present in only the conduction system.137

Hosenpud et al138 reported that in 10 patients with life-threatening arrhythmias in the absence of structural heart disease, EMB demonstrated lymphocytic myocarditis in 2 patients, granulomatous myocarditis in 2 patients, and small-vessel vasculitis in 1 patient. In another series of 14 patients with high-grade ventricular arrhythmias and no structural heart disease, EMB was normal in 6 patients and demonstrated nonspecific abnormalities, predominantly fibrosis, in the other patients. In this series, abnormal biopsy findings did not correlate with induced arrhythmias or prognosis. No specific treatable diagnoses were revealed by biopsy in this series.139 In a third case series, EMB in 12 patients with serious ventricular arrhythmias and structurally normal hearts demonstrated nonspecific abnormalities in 11 patients and acute lymphocytic myocarditis in 1 patient.140 Vignola et al141 reported that in 12 patients with high-grade ventricular arrhythmias and without overt cardiac disease, EMB led to a diagnosis of clinically unsuspected lymphocytic myocarditis in 6 patients. After 6 months of immunosuppressive therapy, ventricular arrhythmia could not be provoked in 5 of the 6 patients.141 Frustaci and colleagues142 reported on the results of noninvasive and invasive evaluation, including right and left heart biopsy, of 17 young patients without overt organic heart disease who were resuscitated from sudden cardiac arrest, 9 of whom were subsequently classified as having structurally normal hearts. Six of these 9 patients appear to have been classified with histological evidence of myocarditis. Interestingly, left ventricular biopsy allowed the diagnoses of myocarditis in 3 patients in whom the diagnosis would not have been made by right ventricular biopsy.142

EMB results in 11 children with paroxysmal or incessant supraventricular tachycardia, the majority of whom had grossly structurally normal hearts, yielded a high incidence of nonspecific histopathologic abnormalities, including hypertrophy and interstitial fibrosis or disarray. Additionally, it was
speculated that the arrhythmia may have lead to the myocardial damage, rather than vice versa.\textsuperscript{143} Teragaki and coworkers\textsuperscript{144} examined the results of EMB in 10 patients with documented AV block without apparent heart disease who also underwent electrophysiological testing. Seven of the 10 patients were found to have evidence of myocardial fibrosis, with either myocyte hypertrophy or disarray. The results of electrophysiological testing did not correlate with the histopathologic findings or severity.\textsuperscript{144} In another report, 19 of 32 patients with various forms of supraventricular

<table>
<thead>
<tr>
<th>Author</th>
<th>Date of Publication</th>
<th>Abnormality</th>
<th>Patients, n</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strain et al\textsuperscript{157}</td>
<td>1983</td>
<td>Ventricular tachycardia or ventricular fibrillation</td>
<td>18</td>
<td>16 of 18 patients (89%) with abnormal findings Non-specific myocellular hypertrophy, interstitial and perivascular fibrosis, and vascular sclerosis in 9 of 18 patients, subacute inflammatory myocarditis in 3 of 18 patients, diffuse abnormalities of the intramyocardial arteries in 2 of 18 patients, and changes consistent with ARVD/C in 2 of 18 patients</td>
</tr>
<tr>
<td>Vignola et al\textsuperscript{141}</td>
<td>1984</td>
<td>Malignant ventricular arrhythmias</td>
<td>12</td>
<td>“Clinically unsuspected myocarditis” in 6 of 12 cases and “early cardiomyopathy” in 3 of 12 cases</td>
</tr>
<tr>
<td>Sugrue et al\textsuperscript{140}</td>
<td>1984</td>
<td>Ventricular arrhythmias</td>
<td>12</td>
<td>11 of 12 patients with histological abnormalities 1 of 12 patients with acute lymphocytic myocarditis</td>
</tr>
<tr>
<td>Morgera et al\textsuperscript{158}</td>
<td>1985</td>
<td>Ventricular tachycardia</td>
<td>10</td>
<td>1 of 6 patients without echocardiographic evidence of ARVD/C or right ventricular cardiomyopathy had evidence of myocarditis</td>
</tr>
<tr>
<td>Hosenpud et al\textsuperscript{138}</td>
<td>1986</td>
<td>Life-threatening arrhythmias</td>
<td>12</td>
<td>Various forms of myocarditis in 4 of 12 patients, vasculitis in 1 of 12 patients, and “cardiomyopathic changes” in 6 of 12 patients</td>
</tr>
<tr>
<td>Dunnigan et al\textsuperscript{159}</td>
<td>1987</td>
<td>Ventricular tachycardia</td>
<td>11</td>
<td>Various nonspecific abnormalities in all 11 of 11 patients</td>
</tr>
<tr>
<td>Kobayashi et al\textsuperscript{145}</td>
<td>1988</td>
<td>Various supraventricular tachycardias</td>
<td>50</td>
<td>Myocarditis changes in 6 of 50 patients, postmyocarditic changes in 15 of 50 patients, and nonspecific abnormalities in 9 of 50 patients</td>
</tr>
<tr>
<td>Nishikawa et al\textsuperscript{160}</td>
<td>1990</td>
<td>Various arrhythmias or AV block</td>
<td>23 (pediatric)</td>
<td>Myocyte hypertrophy, disarrangement of muscle bundles, and/or interstitial fibrosis with or without myocyte degeneration in 7 of 11 atrioventricular block cases, 1 of 6 premature ventricular contraction cases, and 0 of 3 sick sinus syndrome cases</td>
</tr>
<tr>
<td>Frustaci et al\textsuperscript{147}</td>
<td>1991</td>
<td>Lone atrial fibrillation</td>
<td>14</td>
<td>“Cardiomyopathic” changes in 3 of 14 patients, active myocarditis in 3 of 14 patients, and “nonspecific necrosis and/or fibrosis” in 8 of 14 patients</td>
</tr>
<tr>
<td>Sekiguchi et al\textsuperscript{141}</td>
<td>1992</td>
<td>Ventricular tachycardia or premature ventricular contractions</td>
<td>43</td>
<td>“Active myocarditis” in 1 patient and “postmyocarditic” changes in 9 patients</td>
</tr>
<tr>
<td>Oakes et al\textsuperscript{139}</td>
<td>1992</td>
<td>Ventricular arrhythmias</td>
<td>14</td>
<td>Fibrosis in 6 of 14 patients and monocytes containing aminosalicylic acid-positive vacuoles in 1 of 14 patients No specific treatable diagnosis present in any biopsy</td>
</tr>
<tr>
<td>Thongtang et al\textsuperscript{152}</td>
<td>1993</td>
<td>Various dysrhythmias</td>
<td>53</td>
<td>Myocarditis diagnosed in 18 of 53 patients</td>
</tr>
<tr>
<td>Frustaci et al\textsuperscript{142}</td>
<td>1994</td>
<td>Young sudden cardiac death survivors</td>
<td>17 (9 of whom had structurally normal hearts)</td>
<td>Histological diagnosis of myocarditis in 6 of 9 patients with macroscopically structurally normal hearts Left ventricular biopsy revealed a diagnosis of myocarditis in 3 of 7 total study patients with normal right ventricular histology</td>
</tr>
<tr>
<td>Yonesaka et al\textsuperscript{143}</td>
<td>1996</td>
<td>Children with supraventricular tachycardia</td>
<td>11 (4 of whom had cardiomyopathy)</td>
<td>Frequent nonspecific hypertrophy, degeneration, disarray, and endomyocardial changes Speculated that the supraventricular tachycardia causes the histological changes rather than vice versa</td>
</tr>
<tr>
<td>Teragaki et al\textsuperscript{144}</td>
<td>1999</td>
<td>AV block</td>
<td>10</td>
<td>Myocardial fibrosis with hypertrophy and/or disarray in 7 of 10 patients</td>
</tr>
<tr>
<td>Uemura et al\textsuperscript{146}</td>
<td>2001</td>
<td>Second- or third-degree AV block</td>
<td>50</td>
<td>Frequent myocyte hypertrophy, lymphotoxic infiltration, myocyte disarrangement, myocytolysis, and nuclear deformity Myocarditis diagnosed in 6% of patients</td>
</tr>
<tr>
<td>Uemura et al\textsuperscript{148}</td>
<td>2004</td>
<td>Sick sinus syndrome</td>
<td>25</td>
<td>Frequent myocyte hypertrophy, myocyte size variation, myocyte disorganization, myocytolysis, and interstitial large mononuclear cell proliferation</td>
</tr>
</tbody>
</table>
tachycardia and without other clinical abnormalities were found to have some form of myocardial changes, including 6 with myocarditic changes.\textsuperscript{145}

Uemura and colleagues\textsuperscript{146} also reported on the results of EMB in 50 patients with second- or third-degree AV block in whom the cause of the heart block was not clear. Patients with known coronary artery disease, DCM, cardiac sarcoidosis, or "obvious" acute myocarditis were excluded from the study. The results in these patients were also compared with the findings from 12 normal hearts. Biopsy specimens in those with AV block revealed more myocyte hypertrophy, greater fibrosis, and higher lymphocyte counts than in biopsy specimens from normal hearts. In addition, specimens from the group with AV block had variable degrees of myocyte disorganization and disarrangement, myocytolysis, and nuclear deformity. Myocarditis was diagnosed in 3 of the 50 patients (6%).\textsuperscript{146}

Thus, EMB in patients with primary (idiopathic) rhythm abnormalities can be expected to often yield abnormal but nondiagnostic findings. Although EMB may detect otherwise clinically unsuspected myocarditis, the value of this finding in clinical decision making remains controversial. The detection of active myocarditis in a patient with malignant ventricular arrhythmia might theoretically lead to a decision to defer implantation of a defibrillator until the myocarditis has subsided, but such an approach is more theoretical than tested. Eighteen years ago, Mason and O’Connell\textsuperscript{148} classified the indication for EMB in unexplained, life-threatening ventricular tachyarrhythmias as “uncertain,” and it seems there has been little published literature since to change this classification. Therefore, the Writing Group recommends that EMB may be considered in the setting of unexplained ventricular arrhythmias only in exceptional cases in which the perceived likelihood of meaningful prognostic and therapeutic benefit outweighs the procedural risks.

**Clinical Scenario 14**

EMB should not be performed in the setting of unexplained atrial fibrillation. \textit{Class of Recommendation III, Level of Evidence C.}

Frustaci and colleagues\textsuperscript{147} reported on 14 patients with lone atrial fibrillation unresponsive to usual antiarrhythmic therapy who underwent extensive evaluation, including EMB. Some degree of histological abnormalities was present in all patients, with 3 patients showing cardiomyopathic changes, 3 other patients showing active myocarditis (lymphocytic in 2 and eosinophilic in 1), and 8 patients showing nonspecific necrosis and/or fibrosis. The addition of steroid therapy to the patients diagnosed with myocarditis reportedly resulted in reversion to sinus rhythm. The other patients continued to have atrial fibrillation.\textsuperscript{147}

Uemura and colleagues\textsuperscript{148} reported on the results of right ventricular EMB in 25 patients admitted for diagnostic evaluation of “sick sinus syndrome” who did not have underlying cardiac disease such as cardiomyopathy or valvular disease. These results were compared with biopsies from 12 normal autopsied hearts. Compared with normal hearts, biopsies from those with sick sinus syndrome demonstrated a larger mean myocyte transverse diameter, greater myocyte size variation, similar degrees of fibrosis, and similar lymphocyte counts. Histologically abnormal findings such as myocyte disorganization, interstitial mononuclear cells, and endocardial lesions were only seen in those biopsy specimens from patients with sick sinus syndrome. No mention is made of how these findings might have related to clinical management.\textsuperscript{148} On the basis of these reports, the Writing Group recommends that EMB not be performed in the setting of unexplained atrial fibrillation.

**EMB as a Research Tool**

In addition to its clinical roles, EMB may be used to better understand the cellular and molecular pathophysiology of cardiovascular disease. For example, the development of techniques for quantifying gene expression in small amounts of EMB tissue using PCR\textsuperscript{149} led to the finding that recapitulation of the “fetal gene program” that accompanied the development of heart failure could be reversed with normalization of left ventricular function\textsuperscript{150} and that changes in gene expression could be correlated with biochemical and physiological changes in the failing heart.\textsuperscript{151} In addition, serial measures of gene expression are useful in documenting the relationship between biochemical and phenotypic changes in the failing heart in response to either treatment or disease progression.\textsuperscript{152}

More recently, silicon chip–based technology or mRNA expression arrays and protein expression through mass spectroscopy have also been used to assess the biochemistry of the failing heart in vivo. Several reviews on microarrays in cardiovascular diseases have been published.\textsuperscript{153,154} Various studies have identified differentially expressed genes\textsuperscript{155} and clustering gene expression profiles to find functional groupings of genes.\textsuperscript{156}

The Writing Group’s review of several hundred reports involving the use of EMB in cardiovascular disease also revealed a number of clinically relevant and unanswered questions. The utility of novel histological markers of inflammation to define myocarditis and improve on the standard Dallas criteria has only been explored in preliminary studies. The sensitivity of EMB for viral-associated cardiomyopathy is also a key unanswered question. Notably, the relative risks and diagnostic yield of left versus right ventricular biopsy as well as techniques to improve the safety of EMB have not been investigated.
**Disclosures**

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers' Bureau/Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leslie T. Cooper</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kenneth L. Baughman</td>
<td>Brigham and Women’s Hospital</td>
<td>NIH†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Arthur Feldman</td>
<td>Thomas Jefferson University Hospital</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Andrea Frustaci</td>
<td>La Sapienza University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mariell Jessup</td>
<td>University of Pennsylvania</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca*; Medtronic*; ACORN*; GlaxoSmithKline*</td>
<td>None</td>
<td>None</td>
<td>ACORN*; Medtronic*; GlaxoSmithKline*; Ventracor*</td>
<td>None</td>
</tr>
<tr>
<td>Glenn N. Levine</td>
<td>Baylor College of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jagat Narula</td>
<td>University of California, Irvine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Randall C. Starling</td>
<td>Cleveland Clinic Foundation</td>
<td>NIH†</td>
<td>Novartis*; Orquis*; Johnson &amp; Johnson*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Acorn Cardiovascular Inc*; Cardiromems*; Myocor*; Medtronic*; World Heart*</td>
<td>None</td>
</tr>
<tr>
<td>Jeffrey Towbin</td>
<td>Baylor College of Medicine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Renu Virmani</td>
<td>CV Path</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Medtronic*; Guidant*; Abbott Laboratories†; W.L. Gore†; CryoVascular Systems, Inc†; Volcano Therapeutics Inc†; Precient Medical†; Medcon†; Cardiomind, Inc†; Direct Flow†</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

*Modest.
†Significant.
References


38. Narula J, Khaw BA, Dec GW, Palacios IF, Newell JB, Southern JF, Fallon JT, Strauss HW, Haber E, Yasuda T. Diagnostic accuracy of...


The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, the American College of Cardiology, and the European Society of Cardiology
Leslie T. Cooper, Kenneth L. Baughman, Arthur M. Feldman, Andrea Frustaci, Mariell Jessup, Uwe Kuhl, Glenn N. Levine, Jagat Narula, Randall C. Starling, Jeffrey Towbin and Renu Virmani
Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology

Circulation. 2007;116:2216-2233; originally published online October 24, 2007; doi: 10.1161/CIRCULATIONAHA.107.186093
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/116/19/2216

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/